81_FR_10301 81 FR 10262 - National Institute on Drug Abuse; Notice of Closed Meetings

81 FR 10262 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 39 (February 29, 2016)

Page Range10262-10263
FR Document2016-04362

Federal Register, Volume 81 Issue 39 (Monday, February 29, 2016) 
[Federal Register Volume 81, Number 39 (Monday, February 29, 2016)]
[Notices]
[Pages 10262-10263]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-04362]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Multi-site Clinical Trials.
    Date: March 10, 2016.
    Time: 10:30 a.m. to 1:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., 
Room 4245, Rockville, MD 20852, 301-435-1426, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research 
(R21).
    Date: March 11, 2016.
    Time: 12:00 p.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 
4238, MSC 9550, Bethesda, MD 20892, 301-402-6020, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Cutting-Edge Basic Research Awards (CEBRA) (R21).
    Date: March 17, 2016.
    Time: 9:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, National Institutes of Health,

[[Page 10263]]

DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, 301-435-
1426, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; R13 Conference Grant Review (PA13-347).
    Date: March 28, 2016.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., 
Room 4245, Rockville, MD 20852, 301-435-1426, 
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: February 24, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-04362 Filed 2-26-16; 8:45 am]
BILLING CODE 4140-01-P

10262 Federal Register / Vol. 81, No. 39 / Monday, February 29, 2016 / Notices DEPARTMENT OF HEALTH AND provisions set forth in sections The meetings will be closed to the HUMAN SERVICES 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., public in accordance with the as amended. The grant applications and provisions set forth in sections National Institutes of Health contract proposals discussions could 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., disclose confidential trade secrets or as amended. The grant applications and National Heart, Lung, and Blood commercial property such as patentable the discussions could disclose Institute; Notice of Closed Meeting material, and personal information confidential trade secrets or commercial Pursuant to section 10(d) of the concerning individuals associated with property such as patentable material, Federal Advisory Committee Act, as the grant applications, the disclosure of and personal information concerning amended (5 U.S.C. App.), notice is which would constitute a clearly individuals associated with the grant hereby given of the following meeting. unwarranted invasion of personal applications, the disclosure of which The meeting will be closed to the privacy. would constitute a clearly unwarranted public in accordance with the Name of Committee: Arthritis and invasion of personal privacy. provisions set forth in sections Musculoskeletal and Skin Diseases Initial Name of Committee: National Institute on 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Review Group; Arthritis and Musculoskeletal Drug Abuse Special Emphasis Panel; Multi- as amended. The grant applications and and Skin Diseases Clinical Trials Review site Clinical Trials. the discussions could disclose Committee; AMSC Clinical Review Meeting. Date: March 10, 2016. confidential trade secrets or commercial Date: March 15–16, 2016. Time: 10:30 a.m. to 1:30 p.m. property such as patentable material, Time: March 15, 2016, 8:00 a.m. to 5:00 Agenda: To review and evaluate grant and personal information concerning p.m. applications. individuals associated with the grant Agenda: To review and evaluate grant Place: National Institutes of Health, applications. Neuroscience Center, 6001 Executive applications, the disclosure of which Boulevard, Rockville, MD 20852 (Telephone Place: Bethesda Marriott Suites, 6711 would constitute a clearly unwarranted Democracy Boulevard, Bethesda, MD 20817. Conference Call). invasion of personal privacy. Contact Person: Charles H. Washabaugh, Contact Person: Susan O. McGuire, Ph.D., Name of Committee: Heart, Lung, and Ph.D., Scientific Review Officer, Scientific Scientific Review Officer, Office of Blood Initial Review Group; Heart, Lung, and Review Branch NIAMS/NIH, 6701 Extramural Affairs, National Institute on Blood Program Project Review Committee. Democracy Boulevard, Suite 816, Bethesda, Drug Abuse, National Institutes of Health, Date: March 18, 2016. MD 20892, 301–594–4952, washabac@ DHHS, 6001 Executive Blvd., Room 4245, Time: 8:00 a.m. to 1:00 p.m. mail.nih.gov. Rockville, MD 20852, 301–435–1426, Agenda: To review and evaluate grant Name of Committee: National Institute of MCGUIRESO@MAIL.NIH.GOV. applications. Arthritis and Musculoskeletal and Skin This notice is being published less than 15 Place: Hyatt Regency Bethesda, One Diseases Special Emphasis Panel; Clinical days prior to the meeting due to the timing Bethesda Metro Center, 7400 Wisconsin Studies Management. limitations imposed by the review and Avenue, Bethesda, MD 20814. Date: March 17, 2016. funding cycle. Contact Person: Jeffrey H. Hurst, Ph.D., Time: 8:00 a.m. to 5:00 p.m. Name of Committee: National Institute on Scientific Review Officer, Office of Scientific Agenda: To review and evaluate contract Review/DERA, National Heart, Lung, and Drug Abuse Special Emphasis Panel; proposals. Mechanism for Time-Sensitive Drug Abuse Blood Institute, National Institutes of Health, Place: National Institutes of Health/ 6701 Rockledge Drive, Room 7208, Bethesda, Research (R21). NIAMS, One Democracy Plaza, 6701 Date: March 11, 2016. MD 20892, 301–435–0303, hurstj@ Democracy Boulevard, Bethesda, MD 20892. Time: 12:00 p.m. to 1:00 p.m. nhlbi.nih.gov. Contact Person: Kathy ScD Salaita, Chief, Agenda: To review and evaluate grant (Catalogue of Federal Domestic Assistance Scientific Review Branch, Center for applications. Program Nos. 93.233, National Center for Scientific Review, National Institutes of Place: National Institutes of Health, Sleep Disorders Research; 93.837, Heart and Health, 6701 Rockledge Drive, Room 3172, Neuroscience Center, 6001 Executive Vascular Diseases Research; 93.838, Lung MSC 7770, Bethesda, MD 20892, 301–806– Boulevard, Rockville, MD 20852 (Telephone Diseases Research; 93.839, Blood Diseases 8250, salaitak@csr.nih.gov. Conference Call). and Resources Research, National Institutes Contact Person: Hiromi Ono, Ph.D., of Health, HHS) (Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Scientific Review Officer, Office of Dated: February 23, 2016. Musculoskeletal and Skin Diseases Research, Extramural Affairs, National Institute on Michelle Trout, National Institutes of Health, HHS) Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room Program Analyst, Office of Federal Advisory Dated: February 23, 2016. 4238, MSC 9550, Bethesda, MD 20892, 301– Committee Policy. Sylvia Neal, 402–6020, hiromi.ono@nih.gov. [FR Doc. 2016–04233 Filed 2–26–16; 8:45 am] Program Analyst, Office of Federal Advisory This notice is being published less than 15 BILLING CODE 4140–01–P Committee Policy. days prior to the meeting due to the timing [FR Doc. 2016–04236 Filed 2–26–16; 8:45 am] limitations imposed by the review and BILLING CODE 4140–01–P funding cycle. DEPARTMENT OF HEALTH AND Name of Committee: National Institute on HUMAN SERVICES Drug Abuse Special Emphasis Panel; Cutting- DEPARTMENT OF HEALTH AND Edge Basic Research Awards (CEBRA) (R21). National Institutes of Health Date: March 17, 2016. HUMAN SERVICES Time: 9:00 a.m. to 4:00 p.m. National Institute of Arthritis and Agenda: To review and evaluate grant asabaliauskas on DSK5VPTVN1PROD with NOTICES Musculoskeletal and Skin Diseases; National Institutes of Health applications. Notice of Closed Meetings Place: National Institutes of Health, National Institute on Drug Abuse; Neuroscience Center, 6001 Executive Pursuant to section 10(d) of the Notice of Closed Meetings Boulevard, Rockville, MD 20852 (Virtual Federal Advisory Committee Act, as Meeting). amended (5 U.S.C. App.), notice is Pursuant to section 10(d) of the Contact Person: Susan O. McGuire, Ph.D., hereby given of the following meetings. Federal Advisory Committee Act, as Scientific Review Officer, Office of The meetings will be closed to the amended (5 U.S.C. App), notice is Extramural Affairs, National Institute on public in accordance with the hereby given of the following meetings. Drug Abuse, National Institutes of Health, VerDate Sep<11>2014 19:23 Feb 26, 2016 Jkt 238001 PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\29FEN1.SGM 29FEN1

Federal Register / Vol. 81, No. 39 / Monday, February 29, 2016 / Notices 10263 DHHS, 6001 Executive Blvd., Room 4245, Health, 6701 Rockledge Drive, Room 6192, DEPARTMENT OF HEALTH AND Rockville, MD 20852, 301–435–1426, MSC 7804, Bethesda, MD 20892, (301) 806– HUMAN SERVICES mcguireso@mail.nih.gov. 2515, chatterm@csr.nih.gov. Name of Committee: National Institute on This notice is being published less than 15 National Institutes of Health Drug Abuse Special Emphasis Panel; R13 days prior to the meeting due to the timing Conference Grant Review (PA13–347). limitations imposed by the review and Center for Scientific Review; Notice of Date: March 28, 2016. Closed Meetings funding cycle. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant Name of Committee: Center for Scientific Pursuant to section 10(d) of the applications. Review Special Emphasis Panel; Member Federal Advisory Committee Act, as Place: National Institutes of Health, Conflict: Cellular and Physiological amended (5 U.S.C. App.), notice is Neuroscience Center, 6001 Executive Mechanism of Diabetes and Obesity. hereby given of the following meetings. Boulevard, Rockville, MD 20852 (Virtual Date: March 16, 2016 The meetings will be closed to the Meeting). Time: 2:00 p.m. to 5:00 p.m. public in accordance with the Contact Person: Susan O. McGuire, Ph.D., Agenda: To review and evaluate grant provisions set forth in sections Scientific Review Officer, Office of applications. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Extramural Affairs, National Institute on Place: National Institutes of Health, 6701 as amended. The grant applications and Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockledge Drive, Bethesda, MD 20892, the discussions could disclose Rockville, MD 20852, 301–435–1426, (Telephone Conference Call). confidential trade secrets or commercial mcguireso@mail.nih.gov. Contact Person: Hui Chen, MD., Scientific property such as patentable material, (Catalogue of Federal Domestic Assistance Review Officer, Center for Scientific Review, and personal information concerning Program Nos.: 93.279, Drug Abuse and National Institutes of Health, 6701 Rockledge individuals associated with the grant Addiction Research Programs, National Drive, Bethesda, MD 20892, 301–435–1044, applications, the disclosure of which Institutes of Health, HHS) chenhui@csr.nih.gov. would constitute a clearly unwarranted Dated: February 24, 2016. Name of Committee: Center for Scientific invasion of personal privacy. Natasha M. Copeland, Review Special Emphasis Panel; Skeletal Name of Committee: Center for Scientific Program Analyst, Office of Federal Advisory Muscle Biology. Review Special Emphasis Panel; Member Committee Policy. Date: March 21–22, 2016. Conflict: Respiratory Sciences. [FR Doc. 2016–04362 Filed 2–26–16; 8:45 am] Time: 8:00 a.m. to 5:00 p.m. Date: March 17, 2016. Agenda: To review and evaluate grant Time: 8:00 a.m. to 6:00 p.m. BILLING CODE 4140–01–P applications. Agenda: To review and evaluate grant Place: National Institutes of Health, 6701 applications. Rockledge Drive, Bethesda, MD 20892, Place: National Institutes of Health, 6701 DEPARTMENT OF HEALTH AND Rockledge Drive, Bethesda, MD 20892 HUMAN SERVICES (Virtual Meeting). (Virtual Meeting). Contact Person: Daniel F. McDonald, Contact Person: Lawrence E. Boerboom, National Institutes of Health Ph.D., Scientific Review Officer, Center for Ph.D., Chief, CVRS IRG, Center for Scientific Scientific Review, National Institutes of Review, National Institutes of Health, 6701 Center For Scientific Review; Notice of Health, 6701 Rockledge Drive, Room 4110, Rockledge Drive, Room 4130, MSC 7814, Closed Meetings MSC 7814, Bethesda, MD 20892, (301) 435– Bethesda, MD 20892, (301) 435–8367, 1215, mcdonald@csr.nih.gov. boerboom@nih.gov. Pursuant to section 10(d) of the Name of Committee: Center for Scientific Federal Advisory Committee Act, as Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Review Special Emphasis Panel; Small amended (5 U.S.C. App.), notice is Business: Hematology. hereby given of the following meetings. Fogarty Global Brain Disorders. Date: March 17–18, 2016. The meetings will be closed to the Date: March 24–25, 2016. Time: 8:00 a.m. to 6:00 p.m. public in accordance with the Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant provisions set forth in sections Agenda: To review and evaluate grant applications. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., applications. Place: National Institutes of Health, 6701 Place: The Mayflower Hotel, 1127 Rockledge Drive, Bethesda, MD 20892 as amended. The grant applications and (Virtual Meeting). Connecticut Ave. NW., Washington, DC the discussions could disclose Contact Person: Bukhtiar H. Shah, DVM, 20036. confidential trade secrets or commercial Ph.D., Scientific Review Officer, Center for Contact Person: Suzan Nadi, Ph.D., property such as patentable material, Scientific Review, National Institutes of Scientific Review Officer, Center for Health, 6701 Rockledge Drive, Room 4120, and personal information concerning Scientific Review, National Institutes of MSC 7802, Bethesda, MD 20892, (301) 806– individuals associated with the grant Health, 6701 Rockledge Drive, Room 5217B, 7314, shahb@csr.nih.gov. applications, the disclosure of which MSC 7846, Bethesda, MD 20892, 301–435– would constitute a clearly unwarranted Name of Committee: Center for Scientific 1259, nadis@csr.nih.gov. Review Special Emphasis Panel; Member invasion of personal privacy. (Catalogue of Federal Domestic Assistance Conflict: Innate Immunity, Host Defense, and Name of Committee: Center for Scientific Program Nos. 93.306, Comparative Medicine; Microbial Vaccines. Review Special Emphasis Panel; Member 93.333, Clinical Research, 93.306, 93.333, Date: March 22, 2016. Conflict: Cancer Immunology and 93.337, 93.393–93.396, 93.837–93.844, Time: 1:00 p.m. to 4:30 p.m. Immunotherapeutics. 93.846–93.878, 93.892, 93.893, National Agenda: To review and evaluate grant Date: March 1, 2016. applications. asabaliauskas on DSK5VPTVN1PROD with NOTICES Institutes of Health, HHS) Time: 1:00 p.m. to 3:00 p.m. Place: National Institutes of Health, 6701 Agenda: To review and evaluate grant Dated: February 23, 2016. Rockledge Drive, Bethesda, MD 20892 applications. Sylvia Neal, (Virtual Meeting). Place: National Institutes of Health, 6701 Contact Person: Jin Huang, Ph.D., Rockledge Drive, Bethesda, MD 20892, Program Analyst, Office of Federal Advisory Scientific Review Officer, Center for (Telephone Conference Call). Committee Policy. Scientific Review, National Institutes of Contact Person: Malaya Chatterjee, Ph.D., [FR Doc. 2016–04234 Filed 2–26–16; 8:45 am] Health, 6701 Rockledge Drive, Room 4095G, Scientific Review Officer, Center for BILLING CODE 4140–01–P MSC 7812, Bethesda, MD 20892, (301) 435– Scientific Review, National Institutes of 1230, jh377p@nih.gov. VerDate Sep<11>2014 19:23 Feb 26, 2016 Jkt 238001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 E:\FR\FM\29FEN1.SGM 29FEN1


Document Created: 2016-02-27 02:05:29
Document Modified: 2016-02-27 02:05:29
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesMarch 10, 2016.
FR Citation81 FR 10262 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR